Frank X Liu1, Surrey M Walton1, Robert Leipold1, Deborah Isbell1, Thomas A Golper1. 1. Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL, USA; Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA; Evidera, Bethesda, MD, USA; and Vanderbilt University Medical Center, Division of Nephrology and Hypertension, Nashville, TN, USA.
Abstract
BACKGROUND: The economic burden of treating end-stage renal disease (ESRD) continues to grow. As one response, effective January 1, 2011, Medicare implemented a bundled prospective payment system (PPS, including injectable drugs) for dialysis patients. This study investigated the 5-year budget impact on Medicare under the new PPS of changes in the distribution of patients undergoing peritoneal dialysis (PD), in-center hemodialysis (ICHD), and home hemodialysis (HHD). METHODS: An Excel-based budget impact model was created to assess dialysis-associated Medicare costs. The model accounted for dialysis access establishment, the current monthly capitation physician payment for ESRD, Medicare dialysis payments (including start-up costs), training, oral drug costs, and the costs and probabilities of adverse events including access failure, hospitalization for access infection, pneumonia, septicemia, and cardiovascular events. United States Renal Data System (USRDS) data were used to project the US Medicare dialysis patient population across time. The baseline scenario assumed a stable distribution of PD (7.7%), HHD (1.3%) and ICHD (91.0%) over 5 years. Three comparison scenarios raised the proportions of PD and HHD by (1) 1% and 0.5%, (2) 2% and 0.75%, and (3) 3% and 1% each year; a fourth scenario held HHD constant and lowered PD by 1% per year. RESULTS: Under the bundled PPS, scenarios that increased PD and HHD from 7.7% and 1.3% over 5 years resulted in cumulative savings to Medicare of $114.8M (Scenario 1, 11.7% PD and 3.3% HHD at year 5), $232.9M (Scenario 2, 15.7% PD and 4.3% HHD at year 5), and $350.9M (Scenario 3, 19.7% PD and 5.3% HHD at year 5). When the PD population was decreased from 7.7% in 2013 to 3.7% by 2017 with a constant HHD population, the total Medicare payment for dialysis patients increased by over $121.2M. CONCLUSIONS: Under Medicare bundled PPS, increasing the proportion of patients on PD and HHD vs ICHD could generate substantial savings in dialysis-associated costs to Medicare.
BACKGROUND: The economic burden of treating end-stage renal disease (ESRD) continues to grow. As one response, effective January 1, 2011, Medicare implemented a bundled prospective payment system (PPS, including injectable drugs) for dialysis patients. This study investigated the 5-year budget impact on Medicare under the new PPS of changes in the distribution of patients undergoing peritoneal dialysis (PD), in-center hemodialysis (ICHD), and home hemodialysis (HHD). METHODS: An Excel-based budget impact model was created to assess dialysis-associated Medicare costs. The model accounted for dialysis access establishment, the current monthly capitation physician payment for ESRD, Medicare dialysis payments (including start-up costs), training, oral drug costs, and the costs and probabilities of adverse events including access failure, hospitalization for access infection, pneumonia, septicemia, and cardiovascular events. United States Renal Data System (USRDS) data were used to project the US Medicare dialysis patient population across time. The baseline scenario assumed a stable distribution of PD (7.7%), HHD (1.3%) and ICHD (91.0%) over 5 years. Three comparison scenarios raised the proportions of PD and HHD by (1) 1% and 0.5%, (2) 2% and 0.75%, and (3) 3% and 1% each year; a fourth scenario held HHD constant and lowered PD by 1% per year. RESULTS: Under the bundled PPS, scenarios that increased PD and HHD from 7.7% and 1.3% over 5 years resulted in cumulative savings to Medicare of $114.8M (Scenario 1, 11.7% PD and 3.3% HHD at year 5), $232.9M (Scenario 2, 15.7% PD and 4.3% HHD at year 5), and $350.9M (Scenario 3, 19.7% PD and 5.3% HHD at year 5). When the PD population was decreased from 7.7% in 2013 to 3.7% by 2017 with a constant HHD population, the total Medicare payment for dialysis patients increased by over $121.2M. CONCLUSIONS: Under Medicare bundled PPS, increasing the proportion of patients on PD and HHD vs ICHD could generate substantial savings in dialysis-associated costs to Medicare.
Authors: Nancy Neil; David R Walker; Ricardo Sesso; Juan Carlos Blackburn; Elizabeth A Tschosik; Vito Sciaraffia; Fernando García-Contreras; Dimitrie Capsa; Samir K Bhattacharyya Journal: Value Health Date: 2008-08-01 Impact factor: 5.725
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Nancy Neil; Steven Guest; Leslie Wong; Gary Inglese; Samir K Bhattacharyya; Todd Gehr; David R Walker; Thomas Golper Journal: Clin Ther Date: 2009-04 Impact factor: 3.393
Authors: Kirsten Howard; Glenn Salkeld; Sarah White; Stephen McDonald; Steve Chadban; Jonathan C Craig; Alan Cass Journal: Nephrology (Carlton) Date: 2009-02 Impact factor: 2.506
Authors: Richard A Hirth; Marc N Turenne; John R C Wheeler; Tammie A Nahra; Kathryn K Sleeman; Wei Zhang; Joseph A Messana Journal: Am J Kidney Dis Date: 2013-06-13 Impact factor: 8.860
Authors: David C Mendelssohn; Salim K Mujais; Steven D Soroka; John Brouillette; Tomoko Takano; Paul E Barre; Bharati V Mittal; Ajay Singh; Catherine Firanek; Ken Story; Fredric O Finkelstein Journal: Nephrol Dial Transplant Date: 2008-08-28 Impact factor: 5.992
Authors: Eugene Lin; Khristina I Lung; Glenn M Chertow; Jay Bhattacharya; Darius Lakdawalla Journal: Value Health Date: 2021-07-30 Impact factor: 5.101
Authors: Elliot A Baerman; Jennifer Kaplan; Jenny I Shen; Wolfgang C Winkelmayer; Kevin F Erickson Journal: J Am Soc Nephrol Date: 2022-03-21 Impact factor: 14.978
Authors: Caroline E Sloan; Cynthia J Coffman; Linda L Sanders; Matthew L Maciejewski; Shoou-Yih D Lee; Richard A Hirth; Virginia Wang Journal: Clin J Am Soc Nephrol Date: 2019-11-21 Impact factor: 8.237
Authors: Virginia Wang; Cynthia J Coffman; Linda L Sanders; Abby Hoffman; Caroline E Sloan; Shoou-Yih D Lee; Richard A Hirth; Matthew L Maciejewski Journal: Med Care Date: 2021-02-01 Impact factor: 3.178